TickerFacts.

Compare

Nektar Therapeutics vs Lexicon Pharmaceuticals, Inc. vs Cumberland Pharmaceuticals Inc vs Lftd Partners Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearNektar Therapeutics
NKTR		Lexicon Pharmaceuticals, Inc.
LXRX		Cumberland Pharmaceuticals Inc
CPIX		Lftd Partners Inc.
LIFD
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$55.23M$49.80M$44.52M$36.92M
Revenue growth (YoY)-43.9%+60.2%+17.6%-1.1%
Gross marginn/an/a85.0% (computed)34.2%
Operating margin-253.7%-98.2%-6.3%2.5%
Net margin-297.1%-101.1%-6.4%-67.3%
Net income-$164.08M-$50.34M-$2.84M-$24.86M
EPS (Diluted)-$9.73-$0.14-$0.19-$1.68
Operating cash flow-$208.51M-$67.85M$4.93M$1.32M
Free cash flow-$208.68M-$67.85M$4.83M$1.20M
Cash & equivalents$15.12M$34.33M$11.44M$1.77M
Total assets$280.41M$184.99M$76.82M$19.27M
Total liabilities$190.57M$77.45M$52.28M$6.64M
Shareholders' equity$89.83M$107.54M$24.88M$12.63M
Return on year-end equity-182.6%-46.8%-11.4%-196.8%
Shares outstanding20.38M365.85M14.96M14.82M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearNektar TherapeuticsLexicon Pharmaceuticals, Inc.Cumberland Pharmaceuticals IncLftd Partners Inc.
Latest$55.23M
Ended 2025-12-31		$49.80M
Ended 2025-12-31		$44.52M
Ended 2025-12-31		$36.92M
Ended 2025-12-31
1 year earlier$98.43M
Ended 2024-12-31		$31.08M
Ended 2024-12-31		$37.87M
Ended 2024-12-31		$37.33M
Ended 2024-12-31
2 years earlier$90.12M
Ended 2023-12-31		$1.20M
Ended 2023-12-31		$39.55M
Ended 2023-12-31		$51.61M
Ended 2023-12-31
3 years earlier$92.06M
Ended 2022-12-31		$139.0K
Ended 2022-12-31		$42.01M
Ended 2022-12-31		$57.42M
Ended 2022-12-31
4 years earlier$101.91M
Ended 2021-12-31		$298.0K
Ended 2021-12-31		$35.05M
Ended 2021-12-31		$31.66M
Ended 2021-12-31